Evaxion's 2026 Financial Calendar Overview
Evaxion A/S (NASDAQ: EVAX), a forward-thinking clinical-stage TechBio company recognized for its AI-Immunology™ powered vaccines, has recently shared its financial calendar for 2026. This comprehensive plan highlights important dates that all stakeholders should note.
Key Dates to Remember in 2026
The calendar outlines several significant events throughout the year:
March 2026
On March 5, 2026, Evaxion will provide a business update along with the full-year financial results for 2025. This will give investors insight into the company’s performance and future direction.
April 2026
Following this, the Annual General Meeting is scheduled for April 16, 2026, a critical event for shareholders to engage with the company's leadership and discuss important matters.
May and August Updates
The company will continue to keep stakeholders informed with business updates combined with Q1 and Q2 financial results. May 7, 2026, marks the date for the first quarter results, and August 20, 2026, will showcase the outcomes of the second quarter.
End of Year Financial Outlook
The calendar wraps up with the third quarter financial results set for November 19, 2026. This final update will encapsulate the year’s progress and possibly set expectations for future growth strategies.
About Evaxion
Evaxion is not just another biotech firm; it’s at the cutting edge of technology and medicine. With its unique AI-Immunology™ platform, Evaxion leverages artificial intelligence to simplify and innovate the development of immunotherapies targeting cancer, bacterial diseases, and viral infections. By employing advanced predictive models, the company strives to create novel personalized vaccines, setting itself apart in an industry characterized by rapid technological advancement.
Commitment to Innovation
Evaxion’s commitment to improving patient outcomes through innovative treatment options is evident in its clinical-stage pipeline. The company is actively addressing unmet medical needs within oncology and infectious diseases, demonstrating significant initiative in the global healthcare landscape.
Contacting Evaxion
For stakeholders interested in further details or inquiries, they can connect with Evaxion's Investor Relations. Contact Mads Kronborg, Vice President of Investor Relations & Communication, at +45 53 54 82 96 or via email. Their contact information is readily available for those who wish to engage with the company more directly.
Frequently Asked Questions
What is the significance of Evaxion's financial calendar?
The financial calendar serves to inform stakeholders about key upcoming dates for business updates and financial results, ensuring transparent communication.
How does Evaxion's AI-Immunology™ platform work?
This proprietary technology uses artificial intelligence to analyze the human immune system, aiming to develop effective immunotherapies for various diseases.
What are the main events highlighted in the 2026 calendar?
Key events include business updates on March 5, quarterly financial results, and the Annual General Meeting on April 16, among others.
Who can I contact for more information about Evaxion?
Mads Kronborg, the Vice President of Investor Relations & Communication, is the best point of contact for inquiries related to the company.
Why is understanding Evaxion's financial calendar important for investors?
Understanding the financial calendar helps investors stay informed on the company’s performance, providing valuable insights into potential investment decisions.
